Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Consensus Rating of “Hold” from Analysts

Posted by Geri Gentry on May 21st, 2026

Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Get Free Report) has received an average rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $53.60.

A number of equities research analysts recently commented on TVRD shares. Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. BTIG Research reissued a “buy” rating and set a $15.00 price target on shares of Tvardi Therapeutics in a research note on Wednesday, April 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, April 10th.

Read Our Latest Stock Analysis on TVRD

Institutional Trading of Tvardi Therapeutics

Several hedge funds have recently modified their holdings of TVRD. Arax Advisory Partners grew its stake in shares of Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after purchasing an additional 6,173 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $43,000. HRT Financial LP bought a new stake in shares of Tvardi Therapeutics during the fourth quarter valued at approximately $47,000. Finally, XTX Topco Ltd bought a new stake in shares of Tvardi Therapeutics during the fourth quarter valued at approximately $55,000. 44.66% of the stock is owned by institutional investors.

Tvardi Therapeutics Price Performance

NASDAQ TVRD opened at $3.85 on Friday. The firm has a market cap of $36.11 million, a PE ratio of -1.24 and a beta of 0.30. Tvardi Therapeutics has a one year low of $2.75 and a one year high of $43.65. The stock’s 50 day simple moving average is $3.44 and its 200 day simple moving average is $3.86.

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). As a group, equities analysts expect that Tvardi Therapeutics will post -2.1 earnings per share for the current year.

Tvardi Therapeutics Company Profile

(Get Free Report)

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.